News from intarcia therapeutics, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 06, 2016, 10:15 ET Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

 Intarcia Therapeutics, Inc. today announced top-line results from its more than 4,000 patient Cardiovascular Safety Study (FREEDOM-CVO trial),...


Apr 05, 2016, 09:00 ET Intarcia Appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations, Reporting To Chairman & CEO Kurt Graves

Intarcia Therapeutics, Inc., today announced Anthony Hurley has joined the Company in the role of VP, Global Commercial Manufacturing and...


Feb 08, 2016, 12:05 ET Intarcia Appoints Dr. John Yee into New Role of VP, Global Medical Affairs, Safety and Operations, Reporting Directly to Chairman & CEO Kurt Graves

 Intarcia Therapeutics, Inc. today announced the appointment of John Yee, MD, MPH, into the newly created role of Vice President, Head of...


Jan 07, 2016, 11:20 ET Intarcia Therapeutics Announces Upcoming Presentation at 34th Annual J.P. Morgan Healthcare Conference

 Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview at 9:00 am Pacific...


Sep 24, 2015, 10:00 ET Intarcia Announces Acquisition of Phoundry Pharmaceuticals - Second Pipeline Deal of 2015 Secures Novel Peptide Therapeutics to Combine with ITCA 650 Targeting Next Gen Diabetes & Obesity Therapies

Intarcia Therapeutics, Inc. today announced the acquisition of Phoundry Pharmaceuticals, Inc., a privately held biotechnology company based in...


Sep 16, 2015, 10:55 ET Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD

 Intarcia Therapeutics, Inc. today announced the presentation of results from its first two Phase 3 clinical trials (FREEDOM-1 and FREEDOM-1...


Aug 18, 2015, 19:55 ET Intarcia Announces New Top-Line Phase 3 Results For Investigational Therapy ITCA 650 In Type 2 Diabetes

 Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the...


Jun 08, 2015, 08:16 ET Intarcia Announces Presentations At ADA Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes

 Intarcia Therapeutics, Inc. today announced the presentation of  results from its first two phase 3 clinical trials (FREEDOM-1 and...


Jun 05, 2015, 13:25 ET Intarcia's Kurt Graves Named An EY Entrepreneur Of The Year® 2015

Intarcia Therapeutics, Inc. today announced that Kurt Graves, Chairman, President and CEO of Intarcia, has been named an EY Entrepreneur Of The...


Jun 03, 2015, 11:03 ET Intarcia To Announce Key ITCA 650 Phase 3 Findings And Other Data Presentations At Upcoming 75th Scientific Sessions of the American Diabetes Association In Boston

 Intarcia Therapeutics, Inc. today announced its Company-sponsored presentations at the upcoming 75th Scientific Sessions of the American...


Jun 02, 2015, 10:11 ET Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million

Intarcia Therapeutics, Inc. today announced the closing of an additional $75 million from its recently announced synthetic royalty / equity convert...


May 19, 2015, 12:36 ET Intarcia Therapeutics Names Emad Rizk, MD, To Board Of Directors

 Intarcia Therapeutics, Inc. today announced the appointment of Emad Rizk, MD, to its Board of Directors. Dr. Rizk is a well-respected leader...


May 15, 2015, 16:28 ET Intarcia Named To "CNBC Disruptor 50" List: One Of Only Two Biopharma Companies Named

 Intarcia Therapeutics, Inc. today announced it has been named to CNBC's elite Disruptor 50 list, one of only two biopharmaceutical companies...


May 04, 2015, 08:33 ET Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S.

Intarcia Therapeutics, Inc. today announced the appointment of Michael Williams into the newly created role of Chief Operating Officer (COO). Mr....


May 01, 2015, 16:00 ET Intarcia Appoints James P. Brady Vice President, Human Resources

 Intarcia Therapeutics, Inc. today announced the appointment of James P. Brady as Vice President, Human Resources, reporting directly to Kurt...


Apr 27, 2015, 21:55 ET Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation

 Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a...


Mar 19, 2015, 15:41 ET Intarcia And Numab Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications

 Intarcia Therapeutics, Inc. and Numab AG today announced a strategic collaboration focused on the development of once- or twice-yearly...


Nov 11, 2014, 23:50 ET Intarcia And Servier Sign Ex-U.S. Partnership For ITCA 650 In Diabetes; Intarcia Retains Independence & Full Control Of The U.S. & Japan

 Intarcia Therapeutics, Inc. today announced the successful start of a strategic partnership with Servier outside the United States and Japan,...


Oct 01, 2014, 22:35 ET Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results

 Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide,...


Sep 19, 2014, 05:46 ET Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the presentation of positive interim clinical data for its lead candidate ITCA 650 (continuous...


Sep 17, 2014, 08:15 ET Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies

Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of...


Sep 11, 2014, 17:01 ET Intarcia Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q

 Intarcia Therapeutics, Inc. today announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes...


Aug 05, 2014, 09:03 ET Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality

 Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of...


Jun 19, 2014, 10:32 ET Chairman & CEO Kurt Graves Presents First "Key Disruptor Award" to Tom Alessi, Ph.D., for His Innovations in Chemistry and Manufacturing that Transform Medicines For Patients

 Intarcia Therapeutics, Inc. Chairman, President and CEO Kurt Graves late yesterday presented the very first "Chairman's Key Disruptor Award"...


Jun 15, 2014, 09:00 ET Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

  Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74th Scientific Sessions of the American Diabetes...